BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bermejo M, Mangas-sanjuan V, Gonzalez-alvarez I, Gonzalez-alvarez M. Enhancing Oral Absorption of β-Lapachone: Progress Till Date. Eur J Drug Metab Pharmacokinet 2017;42:1-10. [DOI: 10.1007/s13318-016-0369-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Lee KM, Gwon MR, Lee HW, Seong SJ, Yoon YR. The possibility of low isomerization of β-lapachone in the human body. Transl Clin Pharmacol 2021;29:160-70. [PMID: 34621708 DOI: 10.12793/tcp.2021.29.e16] [Reference Citation Analysis]
2 Gomes CL, de Albuquerque Wanderley Sales V, Gomes de Melo C, Ferreira da Silva RM, Vicente Nishimura RH, Rolim LA, Rolim Neto PJ. Beta-lapachone: Natural occurrence, physicochemical properties, biological activities, toxicity and synthesis. Phytochemistry 2021;186:112713. [PMID: 33667813 DOI: 10.1016/j.phytochem.2021.112713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ruiz-Picazo A, Lozoya-Agullo I, González-Álvarez I, Bermejo M, González-Álvarez M. Effect of excipients on oral absorption process according to the different gastrointestinal segments. Expert Opin Drug Deliv 2021;18:1005-24. [PMID: 32842776 DOI: 10.1080/17425247.2020.1813108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Steinmeier J, Kube S, Karger G, Ehrke E, Dringen R. β-Lapachone Induces Acute Oxidative Stress in Rat Primary Astrocyte Cultures that is Terminated by the NQO1-Inhibitor Dicoumarol. Neurochem Res 2020;45:2442-55. [PMID: 32789798 DOI: 10.1007/s11064-020-03104-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Lundberg AP, Francis JM, Pajak M, Parkinson EI, Wycislo KL, Rosol TJ, Brown ME, London CA, Dirikolu L, Hergenrother PJ, Fan TM. Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species. Invest New Drugs 2017;35:134-44. [PMID: 27975234 DOI: 10.1007/s10637-016-0414-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]